Market Summary
USD1.64-0.02
Market Closed-1.20%
NUVB Stock Price
NUVB RSI Chart
NUVB Valuation
NUVB Price/Sales (Trailing)
NUVB Profitability
NUVB Fundamentals
NUVB Revenue
NUVB Earnings
Price Action
52 Week Range
1.559.81
(Low)(High)
Last 7 days
-2.4%
Last 30 days
-20.4%
Last 90 days
-7.3%
Trailing 12 Months
-69.5%
NUVB Financial Health
NUVB Investor Care
Financials for Nuvation Bio
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 54.3% | 7,448,000 | 4,828,000 | 3,548,000 | 3,483,000 | 2,963,000 |
| Operating Expenses | -4.2% | 119,734,000 | 125,009,000 | 118,462,000 | 101,026,000 | 93,318,000 |
| S&GA Expenses | -0.4% | 31,919,000 | 32,062,000 | 29,687,000 | 27,139,000 | 24,281,000 |
| R&D Expenses | -5.5% | 87,815,000 | 92,947,000 | 88,775,000 | 73,887,000 | 69,037,000 |
| EBITDA | -5.1% | -108,279,000 | -103,041,000 | -87,539,000 | -86,664,000 | - |
| EBITDA Margin | 22.8% | -22.43 | -29.04 | -25.13 | -29.25 | - |
| Earnings Before Taxes | 4.0% | -104,199,000 | -108,488,000 | -103,264,000 | -87,739,000 | -86,848,000 |
| EBT Margin | 22.8% | -22.47 | -29.10 | -25.19 | -29.31 | - |
| Net Income | 4.0% | -104,199,000 | -108,488,000 | -103,264,000 | -87,739,000 | -86,848,000 |
| Net Income Margin | 22.8% | -22.47 | -29.10 | -25.19 | -29.31 | - |
| Free Cahsflow | -17.0% | -103,382,000 | -88,390,000 | -107,790,000 | -68,190,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -2.1% | 672 | 686 | 720 | 752 | 776 |
| Current Assets | -2.1% | 667 | 681 | 714 | 748 | 772 |
| Cash Equivalents | -27.1% | 101 | 139 | 102 | 106 | 132 |
| Net PPE | -0.9% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | -8.0% | 17.00 | 19.00 | 27.00 | 28.00 | 30.00 |
| Current Liabilities | -6.1% | 13.00 | 14.00 | 21.00 | 21.00 | 17.00 |
| Shareholder's Equity | -1.9% | 655 | 668 | 693 | 724 | 746 |
| Retained Earnings | -8.5% | -267 | -246 | -218 | -184 | -162 |
| Shares Outstanding | 0.1% | 219 | 218 | 218 | 218 | 218 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 7.0% | -96.10 | -103 | -88.43 | -78.36 | -68.19 |
| Share Based Compensation | 15.5% | 16.00 | 14.00 | 14.00 | 11.00 | 9.00 |
| Cashflow From Investing | 161.0% | 63.00 | -103 | -259 | -459 | -454 |
| Cashflow From Financing | -9.0% | 1.00 | 1.00 | 1.00 | 5.00 | 626 |
Risks for NUVB
What is the probability of a big loss on NUVB?
81.6%
Probability that Nuvation Bio stock will be more than 20% underwater in next one year
76.5%
Probability that Nuvation Bio stock will be more than 30% underwater in next one year.
65.4%
Probability that Nuvation Bio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does NUVB drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Nuvation Bio was unfortunately bought at previous high price.
Drawdowns
Returns for NUVB
Cumulative Returns on NUVB
Which funds bought or sold NUVB recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | -5,177 | 29,823 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | unchanged | - | -745 | 9,255 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -14,356 | 88,644 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | - | -3,000 | - | -% |
2023-02-16 | AXXCESS WEALTH MANAGEMENT, LLC | sold off | -100 | -22,000 | - | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | added | 7.61 | -28,244 | 336,756 | -% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | -2,552 | 14,448 | -% |
2023-02-15 | Virtu Financial LLC | new | - | 31,000 | 31,000 | -% |
2023-02-15 | Point72 Middle East FZE | new | - | 6,015 | 6,015 | -% |
2023-02-15 | JANE STREET GROUP, LLC | added | 0.53 | -48,604 | 303,396 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Nuvation Bio News
Schedule 13G FIlings of Nuvation Bio
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | deep track capital, lp | 3.76% | 8,221,188 | SC 13G/A | |
| Feb 13, 2023 | blackrock inc. | 5.0% | 10,996,735 | SC 13G | |
| Feb 13, 2023 | omega fund v, l.p. | 6.9% | 15,072,340 | SC 13D/A | |
| Feb 09, 2023 | vanguard group inc | 4.55% | 9,932,441 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Jun 23, 2022 | deep track capital, lp | 5.26% | 11,471,281 | SC 13G | |
| Feb 11, 2022 | castle creek arbitrage, llc | 10% | 215,426 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 19, 2021 | omega fund v, l.p. | 13.0% | 28,212,376 | SC 13D | |
| Feb 19, 2021 | hung david | 27.4% | 59,645,012 | SC 13D |
NUVB Fair Value
Nuvation Bio fair value in different scenarios
The table shows the Fair Value estimates for Nuvation Bio for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 0.78 -52.44% | 0.79 -51.83% | 0.81 -50.61% | 0.85 -48.17% | 0.93 -43.29% |
| Current Inflation | 0.78 -52.44% | 0.79 -51.83% | 0.81 -50.61% | 0.84 -48.78% | 0.91 -44.51% |
| Very High Inflation | 0.78 -52.44% | 0.79 -51.83% | 0.80 -51.22% | 0.83 -49.39% | 0.88 -46.34% |
Historical Nuvation Bio Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Nuvation Bio
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 16, 2023 | S-8 | Employee Benefits Plan | |
| Mar 15, 2023 | 10-K | Annual Report | |
| Mar 15, 2023 | 8-K | Current Report | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for NUVB
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-12-05 | FALBERG KATHRYN E | bought | 83,961 | 1.9526 | 43,000 | - |
2022-12-02 | FALBERG KATHRYN E | bought | 93,186 | 1.9827 | 47,000 | - |
2022-12-01 | FALBERG KATHRYN E | bought | 167,599 | 1.9727 | 84,959 | - |
2022-11-30 | FALBERG KATHRYN E | bought | 139,088 | 1.8535 | 75,041 | - |
2022-04-05 | Omega Fund V, L.P. | sold | -14,000,000 | 5.6 | -2,500,000 | - |
2021-12-15 | Omega Fund V, L.P. | sold | -5,035,000 | 10.07 | -500,000 | - |
2021-12-07 | Omega Fund V, L.P. | sold | -13,720,000 | 9.8 | -1,400,000 | - |
2021-11-24 | NODELMAN OLEG | bought | 1,254,860 | 7.6859 | 163,268 | - |
2021-11-24 | NODELMAN OLEG | bought | 167,230 | 7.6859 | 21,758 | - |
2021-11-23 | Omega Fund V, L.P. | sold | -351 | 9.75 | -36.00 | - |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Income Statement
2022-12-31Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
| Operating expenses: | ||
| Research and development | $ 87,815 | $ 69,037 |
| General and administrative | 31,919 | 24,281 |
| Total operating expenses | 119,734 | 93,318 |
| Loss from operations | (119,734) | (93,318) |
| Other income (expense): | ||
| Interest income | 7,448 | 2,963 |
| Investment advisory fees | (872) | (644) |
| Change in fair value of warrants liability | 10,187 | 4,231 |
| Net (loss) gain on marketable securities | (1,228) | (80) |
| Total other income (expense), net | 15,535 | 6,470 |
| Loss before income taxes | (104,199) | (86,848) |
| Provision for income taxes | 0 | 0 |
| Net loss | $ (104,199) | $ (86,848) |
| Net loss per share attributable to common stockholders, basic | $ (0.48) | $ (0.44) |
| Net loss per share attributable to common stockholders, diluted | $ (0.48) | $ (0.44) |
| Weighted average common shares outstanding, basic | 216,721 | 197,887 |
| Weighted average common shares outstanding, diluted | 216,721 | 197,887 |
| Comprehensive loss: | ||
| Net loss | $ (104,199) | $ (86,848) |
| Other comprehensive income (loss), net of taxes: | ||
| Unrealized loss on available-for-sale securities, net | (4,341) | (2,742) |
| Comprehensive loss | $ (108,540) | $ (89,590) |
NUVB Balance Sheet
2022-12-31Consolidated Balance Sheet - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash equivalents | $ 101,099 | $ 132,423 |
| Prepaid expenses and other current assets | 3,819 | 3,642 |
| Marketable securities | 559,915 | 632,969 |
| Interest receivable on marketable securities | 2,485 | 3,039 |
| Total Current Assets | 667,318 | 772,073 |
| Property and equipment, net | 894 | 786 |
| Lease security deposit | 138 | 421 |
| Right of use asset | 3,791 | 2,871 |
| Total Assets | 672,141 | 776,151 |
| Current liabilities | ||
| Accounts payable | 2,139 | 3,925 |
| Current operating lease liabilities | 1,206 | 863 |
| Accrued expenses | 9,816 | 12,137 |
| Total Current Liabilities | 13,161 | 16,925 |
| Warrant Liability | 850 | 11,037 |
| Non-current operating lease liabilities | 3,054 | 2,192 |
| Total Liabilities | 17,065 | 30,154 |
| Commitments and contingencies | ||
| Stockholders' Equity | ||
| Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000,Class B 60,000,000) and 1,174,094,678 (Class A 880,000,000, Class B 294,094,678) shares authorized as of December 31, 2021 and December 31, 2020, respectively, 217,948,568 (Class A 216,948,568, Class B 1,000,000) and 149,042,155 (Class A 91,397,142, Class B 57,645,013) shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively | 927,604 | 909,985 |
| Accumulated deficit | (267,002) | (162,803) |
| Accumulated other comprehensive (loss) income | (5,526) | (1,185) |
| Total Stockholders' Equity | 655,076 | 745,997 |
| Total Liabilities and Stockholders' Equity | $ 672,141 | $ 776,151 |